Por: ABC News Business November 03, 2022
Sliding COVID-19 vaccine sales and rising expenses for Moderna combined to produce a third quarter that missed Wall Street expectations.The vaccine developer also said Thursday that it was dialing back its revenue expectations from advance purchase agreements for this year, as some sales will be deferred to 2023.Moderna also said Thursday that between $2 billion and $3 billion in vaccine sales will be deferred to next year, and the company now... + full article
Associated Press USA Health November 04, 2022
Supply problems have again forced Moderna to delay some COVID-19 vaccine deliveries, a move that surprised Wall Street and contributed to a disappointing third quarter.The vaccine developer said Thursday that short-term issues prompted it to shift some deliveries initially... + más
Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate
Moderna is suing Pfizer over its coronavirus vaccine | The Verge
CNBC USA Health November 03, 2022
In this articleA vial of the Moderna coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, September 8, 2022.Hannah Beier Reuters on Thursday lowered its 2022 sales guidance... + más
WPLG Local 10 USA Politics November 03, 2022
Sliding COVID-19 vaccine sales and rising expenses for Moderna combined to produce a third quarter that missed Wall Street expectations.The vaccine developer also said Thursday that it was dialing back its revenue expectations from advance purchase agreements for this year, as... + más
CNBC USA Health October 12, 2022
Pipettes are seen at the Moderna Therapeutics Inc. lab in Cambridge, Massachusetts, U.S., on Tuesday, Nov. 14, 2017. Moderna this week started testingAdam Glanzman Bloomberg Getty Images and will jointly develop and sell a cancer vaccine that is personalized for individual... + más
Moderna surges as Merck ramps up collaboration on cancer vaccine | The Boston Globe
The Advocate USA Crime October 10, 2022
vaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main competitors of copying Moderna’s technology in order to make their own vaccine.Moderna said Friday that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed... + más
Moderna vs Pfizer: Is it OK to mix and match the updated COVID-19 booster shots? | Los Angeles Times
The Verge USA Health September 24, 2022
Moderna is suing Pfizer over its coronavirus vaccineModerna is suing Pfizer over its coronavirus vaccine / The company is filing patent infringement lawsuits against Pfizerp>span:first-child]:text-black text-blurple>By Aug 26, 2022, 12:37 PM UTC Share this story... + más
Moderna vs. Pfizer: Is it OK to mix and match the updated COVID-19 booster shots? | PennLive
CBS News USA Health September 22, 2022
Vaccinators around the country are reporting weeks-long delays in shipments of Moderna's updated COVID-19 vaccine boosters. The delays come after the Food and Drug Administration flagged concerns at a facility contracted to fill the Moderna's new shots into vials. The... + más
US clears updated COVID boosters targeting newest variants | ABC News
US clears updated COVID boosters targeting newest variants | 10 WBNS
About iurex | Privacy Policy | Disclaimer |